Skip to main content

Table 2 Imaging and tumor characteristics with percentage distribution per SUV max category

From: Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy

 

N (%)

Pretreatment PET SUVmax

  

SUVmax < 5

SUVmax ≥ 5

p

All patients

95

40

55

ns

Histology

    

Squamous

38 (40%)

8 (20%)

30 (54.5%)

.046

Adenocarcinoma

33 (34.7%)

21 (52.5%)

12 (21.8%)

 

NSCLC NOS

24 (25.3%)

11 (27.5%)

13 (23.7%)

 

Tumor Size [median (range)]

2.15 (0.8-5.0) cm

1.95 (0.9-5.0) cm

2.4 (0.8-4.8) cm

.022

T Stage

    

1a

46 (48.4%)

27 (67.5%)

19 (34.5%)

.013

1b

30 (31.6%)

7 (17.5%)

23 (41.8%)

 

2a

19 (20%)

6 (15%)

13 (23.7%)

 
  1. Tumor demographics and SUVmax distributions showing tendency for squamous cell histology and larger size to be of increasing SUVmax.